{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:05:17Z","timestamp":1792591517595,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.yebeh.2025.110787","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T23:31:29Z","timestamp":1760657489000},"page":"110787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Cenobamate in pediatric epilepsy and developmental and epileptic encephalopathies: Efficacy, safety, and syndrome-specific considerations"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5154-8717","authenticated-orcid":false,"given":"Debopam","family":"Samanta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2025.110787_b0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/neurolint13020026","article-title":"Cenobamate, a sodium channel inhibitor and positive allosteric modulator of GABA(A) ion channels, for partial onset seizures in adults: a comprehensive review and clinical implications","volume":"13","author":"Latimer","year":"2021","journal-title":"Neurol Int"},{"key":"10.1016\/j.yebeh.2025.110787_b0010","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond","volume":"35","author":"L\u00f6scher","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2025.110787_b0015","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/epi.16832","article-title":"The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ?","volume":"62","author":"L\u00f6scher","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2025.110787_b0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0030","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40265-019-01250-6","article-title":"Cenobamate: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2025.110787_b0040","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s40120-024-00634-5","article-title":"Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: evidence from the first interim analysis of the bless study","volume":"13","author":"Lattanzi","year":"2024","journal-title":"Neurol Ther"},{"key":"10.1016\/j.yebeh.2025.110787_b0045","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","article-title":"Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis","volume":"34","author":"Lattanzi","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2025.110787_b0050","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2025.110787_b0055","article-title":"The efficacy and safety of third-generation antiseizure medications and non-invasive brain stimulation to treat refractory epilepsy: a systematic review and network meta-analysis study","volume":"14","author":"Yang","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109653","article-title":"Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: a systematic review and network meta-analysis","volume":"152","author":"Tong","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108429","article-title":"Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures","volume":"126","author":"Privitera","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0070","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.seizure.2024.04.004","article-title":"A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: a systematic review and network meta-analysis","volume":"118","author":"Mulheron","year":"2024","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110787_b0075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","article-title":"Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis","volume":"82","author":"Lattanzi","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2025.110787_b0080","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/epi.17549","article-title":"Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a \u201creal-world\u201d retrospective study","volume":"64","author":"Pe\u00f1a-Ceballos","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.seizure.2023.07.026","article-title":"Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study","volume":"111","author":"Beltr\u00e1n-Corbellini","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110787_b0090","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.3390\/jcm14176302","article-title":"Perampanel, brivaracetam, cenobamate, stiripentol, and ganaxolone in lennox-gastaut syndrome: a comprehensive narrative review","volume":"14","author":"Samanta","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.yebeh.2025.110787_b0095","doi-asserted-by":"crossref","unstructured":"Labiner K, Stern S, Wade C, Weingarten M. Effectiveness of Cenobamate in Pediatric Patients with Intractable Focal Seizures: A Retrospective Claims-based Analysis (P2-1.003). In: Neurology: Lippincott Williams & Wilkins Hagerstown, MD; 2024. p. 3713.","DOI":"10.1212\/WNL.0000000000205333"},{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2025.110787_b0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/epi.18303","article-title":"Cenobamate efficacy in specific populations","volume":"66","author":"Klein","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2022.01.001","article-title":"Initial real-world experience with cenobamate in adolescents and adults: a single center experience","volume":"129","author":"Elliott","year":"2022","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108679","article-title":"Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: a single-center retrospective study","volume":"130","author":"Varughese","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.950171","article-title":"Real-world experience treating pediatric epilepsy patients with cenobamate","volume":"13","author":"Makridis","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0120","unstructured":"Gustkey D FJ, Jarrar R, Troester M, Williams K, Wilfong A. Retrospective Chart Review of Cenobamate in Pediatric Epilepsy In: Annual Meeting of the American Epilepsy Society. December 4, 2021; Chicago, IL."},{"key":"10.1016\/j.yebeh.2025.110787_b0125","unstructured":"Peters Haley TA, Tabibzadeh Nathan, Seehra Gurpreet, Moyen Sariha, Nariai Hiroki, Rajaraman Rajsekar, Sankar Raman, Hussain Shaun. Cenobamate treatment of children with refractory epilepsy: the UCLA experience. In: American Epilepsy Society meeting. Los Angeles, California, USA Presented 12\/7\/2024."},{"key":"10.1016\/j.yebeh.2025.110787_b0130","doi-asserted-by":"crossref","DOI":"10.1111\/epi.18586","article-title":"Real-world use of cenobamate in pediatric focal epilepsies and developmental epileptic encephalopathies: a multicenter retrospective series","author":"Soto-Insuga","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0135","article-title":"Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2025.110787_b0140","doi-asserted-by":"crossref","DOI":"10.1177\/08830738251357348","article-title":"Adverse effects of cenobamate in pediatric epilepsy: demographic considerations","author":"Iwamoto","year":"2025","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0145","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/epi.17007","article-title":"Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study","volume":"62","author":"French","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0150","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaneurol.2021.2480","article-title":"Suicidality risk of newer antiseizure medications: a meta-analysis","volume":"78","author":"Klein","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0155","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s10072-024-07864-3","article-title":"Drug-induced liver injury during valproic acid and cenobamate coadministration: a direct consequence or an unforeseen event?","volume":"46","author":"Giannelli","year":"2025","journal-title":"Neurol Sci"},{"key":"10.1016\/j.yebeh.2025.110787_b0160","unstructured":"Cenobamate. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012."},{"key":"10.1016\/j.yebeh.2025.110787_b0165","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1535-7511.2005.00060.x","article-title":"Lamotrigine-induced rash: can we stop worrying?","volume":"5","author":"Kanner","year":"2005","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2025.110787_b0170","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/epi.17935","article-title":"A global update on cenobamate based on real-world experience in over 100\u2009000 patients","volume":"65","author":"Ferrari","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0175","doi-asserted-by":"crossref","unstructured":"Rissardo JP, Fornari Caprara AL. Cenobamate (YKP3089) and Drug-resistant epilepsy: a review of the literature. Medicina (Kaunas) 2023;59.","DOI":"10.3390\/medicina59081389"},{"key":"10.1016\/j.yebeh.2025.110787_b0180","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/cpdd.1077","article-title":"A phase 1 clinical study evaluating the effects of cenobamate on the QT interval","volume":"11","author":"Darpo","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.yebeh.2025.110787_b0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/epi4.12475","article-title":"FDA safety warning on the cardiac effects of lamotrigine: an advisory from the Ad Hoc ILAE\/AES task force","volume":"6","author":"French","year":"2021","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2025.110787_b0190","doi-asserted-by":"crossref","DOI":"10.1111\/epi.18481","article-title":"Cenobamate-associated weight loss (Cenobaweight study)","author":"Hashem","year":"2025","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2025.110787_b0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/epi.18304","article-title":"Improving the tolerability of antiseizure medications: when and how to use cenobamate and other new antiseizure medications","volume":"66","author":"Krauss","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0200","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics drug-drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2025.110787_b0205","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/epi4.12959","article-title":"Treatment simplification to optimize cenobamate effectiveness and tolerability: a real-world retrospective study in Spain","volume":"9","author":"Rodr\u00edguez-Uranga","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2025.110787_b0210","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2174\/1871527321666220113110044","article-title":"Cenobamate: a review of its pharmacological properties, clinical efficacy and tolerability profile in the treatment of epilepsy","volume":"22","author":"Barbieri","year":"2023","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.yebeh.2025.110787_b0215","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/epi.17822","article-title":"The extent of cytochrome P450 3A induction by antiseizure medications: a systematic review and network meta-analysis","volume":"65","author":"Cohen","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108270","article-title":"Practical guidance for the management of adults receiving adjunctive cenobamate for the treatment of focal epilepsy-expert opinion","volume":"123","author":"Steinhoff","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0225","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","article-title":"Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations","volume":"11","author":"Smith","year":"2022","journal-title":"Neurol Ther"},{"key":"10.1016\/j.yebeh.2025.110787_b0230","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1571376","article-title":"Increase of Brivaracetam serum concentration with introduction of Cenobamate","volume":"16","author":"Bender","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2025.110787_b0235","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/epi4.12936","article-title":"Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures","volume":"9","author":"Carre\u00f1o","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2025.110787_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2024.107306","article-title":"Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study","volume":"200","author":"Aboumatar","year":"2024","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110787_b0245","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/epi.17515","article-title":"A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam","volume":"64","author":"Elakkary","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107242","article-title":"Dose reduction and discontinuation of concomitant antiseizure medications after initiating cenobamate: A retrospective review","volume":"197","author":"Becker","year":"2023","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110787_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109156","article-title":"The cenobamate-clobazam interaction- evidence of synergy in addition to pharmacokinetic interaction","volume":"142","author":"Osborn","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107612","article-title":"Management of lennox-gastaut syndrome beyond childhood: a comprehensive review","volume":"114","author":"Samanta","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0265","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/14656566.2025.2516630","article-title":"Current and emerging pharmacotherapies in Lennox-Gastaut syndrome","volume":"26","author":"Samanta","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2025.110787_b0270","doi-asserted-by":"crossref","DOI":"10.1111\/epi.18544","article-title":"Comparative efficacy of neuromodulation therapies in Lennox-Gastaut syndrome: a systematic review and meta-analysis of vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation","author":"Samanta","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2024.107499","article-title":"Neuromodulation strategies in lennox-gastaut syndrome: practical clinical guidance from the pediatric epilepsy research consortium","volume":"210","author":"Samanta","year":"2025","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110787_b0280","article-title":"Antiseizure medications for Lennox-Gastaut syndrome: comprehensive review and proposed consensus treatment algorithm","volume":"164","author":"Samanta","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0285","article-title":"Cognitive and behavioral impact of antiseizure medications, neuromodulation, ketogenic diet, and surgery in Lennox-Gastaut syndrome: a comprehensive review","volume":"164","author":"Samanta","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2025.110660","article-title":"Efficacy, safety and tolerability of adjunctive cenobamate in pediatric and adult patients with Lennox Gastaut syndrome","volume":"172","author":"Pong","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0295","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s40120-025-00779-x","article-title":"Cenobamate for adjunctive treatment in adult and pediatric patients with refractory lennox-gastaut syndrome: a retrospective chart review","volume":"14","author":"Keough","year":"2025","journal-title":"Neurol Ther"},{"key":"10.1016\/j.yebeh.2025.110787_b0300","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.seizure.2025.05.011","article-title":"Effectiveness and safety of cenobamate in Lennox-Gastaut syndrome: a multicenter real-world study in Spain","volume":"131","author":"Aguilar-Amat Prior","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110787_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1209487","article-title":"Cenobamate significantly improves seizure control in intellectually disabled patients with drug-resistant epilepsy and allows drug load reduction","volume":"14","author":"Friedo","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0310","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010129","article-title":"Treatment with cenobamate in adult patients with lennox-gastaut syndrome: a case series","volume":"12","author":"Falcicchio","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.yebeh.2025.110787_b0315","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/epi.18308","article-title":"A multicenter cohort study on the efficacy, retention, and tolerability of cenobamate in patients with developmental and epileptic encephalopathies","volume":"66","author":"Buhleier","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0320","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10072-024-07700-8","article-title":"Safety and effectiveness of cenobamate in down syndrome: a case report","volume":"46","author":"Corniello","year":"2025","journal-title":"Neurol Sci"},{"key":"10.1016\/j.yebeh.2025.110787_b0325","doi-asserted-by":"crossref","unstructured":"Keough K, Stern S, Wade C, Weingarten M. Effectiveness of Cenobamate in Pediatric Patients With Lennox-Gastaut Syndrome: A Retrospective Claims-based Analysis (P1-1.001). In: Neurology: Lippincott Williams & Wilkins Hagerstown, MD; 2024. p. 3535.","DOI":"10.1212\/WNL.0000000000205211"},{"key":"10.1016\/j.yebeh.2025.110787_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.110171","article-title":"A comprehensive review of evolving treatment strategies for Dravet syndrome: insights from randomized trials, meta-analyses, real-world evidence, and emerging therapeutic approaches","volume":"162","author":"Samanta","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0335","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pediatrneurol.2025.04.010","article-title":"Current and emerging precision therapies for developmental and epileptic encephalopathies","volume":"168","author":"Samanta","year":"2025","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0340","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1111\/epi.17427","article-title":"Successful treatment of adult Dravet syndrome patients with cenobamate","volume":"63","author":"Makridis","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0345","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200133","article-title":"Cenobamate in generalized epilepsy and combined generalized and focal epilepsy","volume":"13","author":"Agashe","year":"2023","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.yebeh.2025.110787_b0350","article-title":"Successful treatment of pediatric patient with Dravet syndrome with cenobamate: case report","volume":"13","author":"Lobanov","year":"2025","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.yebeh.2025.110787_b0355","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/epi.18426","article-title":"Lack of effectiveness and seizure worsening with cenobamate in pediatric patients with Dravet syndrome","volume":"66","author":"Cagigal","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0360","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/14656566.2025.2517352","article-title":"Potential of cenobamate as a broad-spectrum antiseizure medication","volume":"26","author":"Melnick","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2025.110787_b0365","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3389\/fphar.2020.01276","article-title":"Epilepsy-related voltage-gated sodium channelopathies: a review","volume":"11","author":"Menezes","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2025.110787_b0370","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/epi.16752","article-title":"Epilepsy with myoclonic-atonic seizures (Doose syndrome): clarification of diagnosis and treatment options through a large retrospective multicenter cohort","volume":"62","author":"Nickels","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2025.03.012","article-title":"Cenobamate in developmental and epileptic encephalopathies and generalized epilepsies: a case report on epilepsy with myoclonic-atonic seizures and systematic review of current evidence","volume":"129","author":"Vlakou","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110787_b0380","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1111\/epi.18115","article-title":"POLR3B is associated with a developmental and epileptic encephalopathy with myoclonic-atonic seizures and ataxia","volume":"65","author":"Symonds","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0385","article-title":"Precision therapeutics in lennox-gastaut syndrome: targeting molecular pathophysiology in a developmental and epileptic encephalopathy","volume":"12","author":"Samanta","year":"2025","journal-title":"Children (Basel)"},{"key":"10.1016\/j.yebeh.2025.110787_b0390","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/epi.18257","article-title":"Cenobamate as add-on treatment for SCN8A developmental and epileptic encephalopathy","volume":"66","author":"Gjerulfsen","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0395","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pediatrneurol.2020.03.008","article-title":"An updated review of tuberous sclerosis complex-associated autism spectrum disorder","volume":"109","author":"Samanta","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.110123","article-title":"Evolving treatment strategies for early-life seizures in Tuberous Sclerosis Complex: a review and treatment algorithm","volume":"161","author":"Samanta","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0405","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pediatrneurol.2024.09.023","article-title":"Cenobamate's efficacy for seizure treatment in tuberous sclerosis complex","volume":"161","author":"Aungaroon","year":"2024","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0410","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pediatrneurol.2024.08.009","article-title":"Mammalian target of rapamycin inhibitor levels decrease under cenobamate treatment","volume":"161","author":"Becker","year":"2024","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0415","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.seizure.2025.07.018","article-title":"Severe epilepsy phenotypes in adults with succinic semialdehyde dehydrogenase deficiency: novel clinical and therapeutic insights from an Italian multicenter retrospective cohort study","volume":"131","author":"Canafoglia","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110787_b0420","unstructured":"Sachdeo Rajesh SR. Cenobamate provides significant reduction in seizure activity in patients with infantile spasms. In: American Epilepsy Society Annual Meeting. Los Angeles, CA, USA. 12\/7\/2024.; 2024."},{"key":"10.1016\/j.yebeh.2025.110787_b0425","article-title":"Case report: LAMC3-associated cortical malformations: Case report of a novel stop-gain variant and literature review","volume":"13","author":"Falcicchio","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.yebeh.2025.110787_b0430","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/19418744221147083","article-title":"Safe use of cenobamate in super refractory status epilepticus: a case series","volume":"13","author":"Carlson","year":"2023","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.yebeh.2025.110787_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2025.110472","article-title":"Seizure-type-specific treatment responses in Lennox-Gastaut Syndrome: a comprehensive review of pharmacological, neuromodulatory, dietary, and surgical therapies","volume":"170","author":"Samanta","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0440","series-title":"Jasper's basic mechanisms of the epilepsies","first-page":"1387","article-title":"Animal Models of Pharmacoresistant Epilepsy","author":"Guignet","year":"2024"},{"key":"10.1016\/j.yebeh.2025.110787_b0445","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26157029","article-title":"The pharmacokinetic and pharmacodynamic relationship of clinically used antiseizure medications in the maximal electroshock seizure model in rodents","volume":"26","author":"Bettio","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.yebeh.2025.110787_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109898","article-title":"Cenobamate suppresses seizures without inducing cell death in neonatal rats","volume":"158","author":"Witherspoon","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e18920","article-title":"Anticonvulsant effects of cenobamate in chemically and electrically induced seizure models in rodents","volume":"9","author":"Melnick","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.yebeh.2025.110787_b0460","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1136\/jnnp-2020-323524","article-title":"Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial","volume":"91","author":"Vossler","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2025.110787_b0465","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1212\/WNL.0000000000007894","article-title":"Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089)","volume":"93","author":"Kasteleijn-Nolst Trenite","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2025.110787_b0470","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1111\/epi.17662","article-title":"Sudden unexpected death in epilepsy during cenobamate clinical development","volume":"64","author":"Rosenfeld","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107796","article-title":"Cenobamate treatment of focal-onset seizures: Quality of life and outcome during up to eight years of treatment","volume":"116","author":"Elizebath","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0480","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.seizure.2022.10.004","article-title":"Effects of cenobamate on cognitive performance of epilepsy patients","volume":"102","author":"Schuetz","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110787_b0485","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/epi4.12857","article-title":"Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy","volume":"9","author":"Catal\u00e1n-Aguilar","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2025.110787_b0490","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40263-025-01196-2","article-title":"The Effects of cenobamate and its dosage on cognition: a retrospective longitudinal study in 84 individuals with epilepsy","volume":"39","author":"Witt","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2025.110787_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109605","article-title":"Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies","volume":"151","author":"Krauss","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0500","article-title":"Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study","volume":"15","author":"Assenza","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0505","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/epi.17564","article-title":"Failure to use new breakthrough treatments for epilepsy","volume":"64","author":"Klein","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0510","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.seizure.2024.12.010","article-title":"Impact of lifetime antiepileptic drug history on cenobamate efficacy in adults with focal epilepsy","volume":"125","author":"Martinez-Lizana","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110787_b0515","doi-asserted-by":"crossref","DOI":"10.1111\/epi.18576","article-title":"Treatment of epilepsy using newer antiseizure medications: a retrospective cohort study of prescription patterns in Sweden 2013-2022","author":"Bolin","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110787_b0520","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40120-025-00781-3","article-title":"Early introduction of cenobamate in uncontrolled focal epilepsy: insights from a structured controversy","volume":"14","author":"Labate","year":"2025","journal-title":"Neurol Ther"},{"key":"10.1016\/j.yebeh.2025.110787_b0525","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70229","article-title":"The effectiveness of cenobamate in patients treated with vagus nerve stimulation for drug resistant epilepsy","volume":"32","author":"Hogeveen","year":"2025","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2025.110787_b0530","article-title":"Synergistic seizure reduction in patient with persistently elevated N-desmethylclobazam levels, CYP450 genetic polymorphism, and responsive neurostimulator targeting centromedian nuclei of bilateral thalami","volume":"31","author":"Zillgitt","year":"2025","journal-title":"Epilepsy Behav Rep"},{"key":"10.1016\/j.yebeh.2025.110787_b0535","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s40120-024-00651-4","article-title":"Presurgical use of cenobamate for adult and pediatric patients referred for epilepsy surgery: expert panel recommendations","volume":"13","author":"Laxer","year":"2024","journal-title":"Neurol Ther"},{"key":"10.1016\/j.yebeh.2025.110787_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2025.107647","article-title":"Electrographic seizures on responsive neurostimulation: an early and objective measure of response to cenobamate","volume":"218","author":"Aboumatar","year":"2025","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110787_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106952","article-title":"Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: post hoc analysis of a phase 3, multicenter, open-label study","volume":"184","author":"Abou-Khalil","year":"2022","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110787_b0550","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14737167.2022.2107507","article-title":"Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain","volume":"22","author":"\u00c1ngel Calleja","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.yebeh.2025.110787_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109350","article-title":"Value contribution of cenobamate for the treatment of Focal-Onset Seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective Multi-Criteria Decision Analysis (MCDA)","volume":"145","author":"Falip","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0560","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s10198-022-01519-w","article-title":"Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy","volume":"24","author":"Flint","year":"2023","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.yebeh.2025.110787_b0565","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/13696998.2024.2443338","article-title":"Budget impact analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands","volume":"28","author":"Li","year":"2025","journal-title":"J Med Econ"},{"key":"10.1016\/j.yebeh.2025.110787_b0570","first-page":"118","article-title":"Cost-effectiveness of cenobamate as a therapeutic alternative for the treatment of focal epilepsy in adults with inadequate seizure control","volume":"12","author":"Paoletti","year":"2025","journal-title":"Glob Reg Health Technol Assess"},{"key":"10.1016\/j.yebeh.2025.110787_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.109054","article-title":"Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain","volume":"139","author":"Villanueva","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110787_b0580","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1080\/13696998.2025.2520182","article-title":"Budget impact analysis of cenobamate, a novel adjunctive therapy for the treatment of drug resistant focal onset seizures, from the Belgian healthcare payer perspective","volume":"28","author":"Vonck","year":"2025","journal-title":"J Med Econ"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502500527X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502500527X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:44:55Z","timestamp":1763747095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502500527X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":116,"alternative-id":["S152550502500527X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110787","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cenobamate in pediatric epilepsy and developmental and epileptic encephalopathies: Efficacy, safety, and syndrome-specific considerations","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110787"}}